Phase 1 trial at UH Seidman Cancer Center tests BAFF CAR T-cells, a new multiple myeloma treatment, for relapsed patients.

A Phase 1 trial at UH Seidman Cancer Center tests BAFF CAR T-cells, a new multiple myeloma treatment targeting three receptors (BAFF-R, BCMA, and TACI) for relapsed patients. Led by Dr. Leland Metheny, the trial aims to determine a safe dose for Phase II trials and evaluate BAFF CAR T-cells' activity, involving 20 patients. The novel therapy offers more treatment options and reduces the risk of antigen escape, conducted through an agreement with Luminary Therapeutics.

August 14, 2024
5 Articles

Further Reading